Skip to main content
XGN
NASDAQ Industrial Applications And Services

Exagen Q2 Revenue Jumps 16% on 11% Test Volume Growth, Loss Narrows Sharply

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$5.66
Mkt Cap
$113.068M
52W Low
$2.59
52W High
$12.23
52W Position info
119% above low
Off High info
54% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

XGN has more than doubled off its 52-week low of $2.59.

Summary

Exagen's Q2 2026 revenue grew 15.9% to $19.9M, with AVISE CTD test volume up 11% and ASP up 4%. Net loss narrowed to $3.2M, and cash of $24.6M provides a 12-month runway.


Key Events · Earnings and Guidance · XGN

  • Revenue Growth Accelerates

    Q2 2026 revenue of $19.9M, up 15.9% YoY, driven by 11% AVISE CTD test volume growth and 4% ASP increase to $446.

  • Loss Narrows, Margins Improve

    Net loss of $3.2M vs. $4.4M in Q2 2025; gross margin expanded to 61.3% from 60.4%.

  • Cash Runway Confirmed

    Cash and equivalents of $24.6M as of June 30, 2026, sufficient to fund operations for at least 12 months.

  • Debt Facility Amended

    First Amendment to Perceptive term loan terminated the $10M Tranche C, extended Tranche B availability to Sept 30, 2026, and revised financial covenants.


Analysis · XGN · Industrial Applications And Services

A strong second quarter underscores Exagen's ongoing turnaround, with revenue climbing 15.9% to $19.9 million. The advance was fueled by an 11% rise in AVISE CTD test volume and a 4% improvement in average selling price. Net loss shrank to $3.2 million from $4.4 million a year ago, while gross margin expanded to 61.3%. Management ended the quarter with $24.6 million in cash, which it says is enough to fund operations for at least the next twelve months. The results reinforce the recovery narrative that has been building since late 2022, as the new CEO's strategy delivers consistent top-line growth and better operating leverage. Also disclosed are an amendment to the Perceptive term loan—terminating one tranche and extending another—and a new office lease in Carlsbad, signaling confidence in future growth.

At the time of this filing, XGN was trading at $5.66 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $113.1M. The 52-week trading range was $2.59 to $12.23. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XGN - Latest Insights

XGN
Aug 04, 2026, 8:12 AM EDT
Source: Reuters
Importance Score:
8
XGN
Aug 04, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
8
XGN
Jun 01, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
XGN
May 11, 2026, 9:17 AM EDT
Filing Type: 10-Q
Importance Score:
7
XGN
May 11, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
7